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ABSTRACT  
Purpose: Intra-arterial mechanical thrombectomy (MT) combined with appropriate 
patient selection (image-based selection of has significantly better clinical outcomes 
compared with intravenous thrombolysis (IVT) for acute ischaemic stroke patients with 
large artery occlusion) yields improved clinical outcomes. We conducted a systematic 
review and meta-analysis, with trial sequential analysis (TSA) to understand the 
benefits, risks and impact of new trials reporting in 2016 on the magnitude/certainty of 
the estimates impact of trials reporting in 2016 on for clinical effectiveness and safety of 
MT. 
Method: Random effects models were conducted of randomised clinical trials 
comparing MT (stent retriever or modern aspiration devices) with/without adjuvant 
intravenous thrombolysis (IVT) with IVT and other forms of best medical/supportive 
care in the treatment of acute ischaemic stroke. Study inclusion and risk of bias were 
assessed independently by two reviewers. Functional independence (mRS 0-2) and 
mortality at 90 days, including symptomatic intracranial haemorrhage (SICH) rate were 
extracted. TSA established the strength of the evidence derived from the meta-analyses. 
Findings: Eight trials of MT including with a total sample size of 1,841 (916 patients 
treated with MT and 925 treated without MT) 916 patients treated using MT fulfilled 
review inclusion criteria. The three most recent trials increased more precisely defined 
certainty of the mid-point estimate for the effectiveness of MT (mRS 0 to 2; OR = 2.07, 
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95% CI = 1.70 to 2.51 based on data from eight trials versus OR = 2.39, 95% CI = 1.88 
to 3.04 based on data from five trials). Meta-analyses showed no effect on mortality 
(OR = 0.81, 95% CI = 0.61 to 1.07) or SICH (OR = 1.22, 95% CI = 0.80 to 1.85) as 
found in analysis of first five trials. (mRS 0-2; OR = 2.07, 95% CI = 1.70 to 2.51) and 
mortality. Meta-analyses showed no effect on certainty around SICH. TSA indicated 
that the information size requirement was fulfilled to conclude the evidence for MT is 
robust.  
Discussion: The impact of three recent trials on effectiveness and safety of MT was a 
more accurate precise pooled effect size for functional independence. TSA 
demonstrated sufficient evidence for effectiveness and safety of MT. 
Conclusion: No further trials of MT versus IVT no MT alone are indicated to establish 
clinical effectiveness. Uncertainty remains as to whether MT reduces mortality or 
increases risk of SICH. 
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INTRODUCTION 
The benefits of intravenous thrombolysis with recombinant tissue plasminogen activator 
(IV rt-PA) for acute ischaemic stroke are well-known, time dependent (with earlier 
treatment within the 4.5 hour treatment window associated with better functional 
outcomes) and encapsulated by the aphorism ‘Time is Brain’1-3. 
 
Despite the efficacy of intravenous thrombolysis (IVT) in reducing post-stroke 
disability, recanalisation (restoration of blood flow through a blocked artery) occurs in 
only ~10 to 45% of patients with large artery occlusion (LAO) depending on site/length 
of occlusion4,5. A number of approaches are currently being explored to increase IVT 
recanalisation rates, including use of more fibrin selective thrombolytic drugs, 
ultrasound and adjunctive anticoagulant therapy. None are yet proven. 
 
There is overwhelming evidence that MT achieves significantly higher recanalisation 
rates than IV rt-PA for LAO6 and better clinical outcomes with a 13 to 31% absolute 
increase in patients recovering from acute stroke to be independent in activities of daily 
living. MT is not associated with an increased risk of symptomatic intracranial 
haemorrhage (SICH) or mortality7,8.  
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Meta-analyses of randomised controlled trials (RCTs) have since been published9-11, 
each of which has taken a slightly different approach to inclusion criteria; all of which 
find that MT is an effective treatment with reduced disability rates. The most robust of 
these is likely to be the individual patient meta-analysis, based on data from 1,287 
patients (634 MT and 653 standard care). The results suggest that MT led to 
significantly reduced disability at 90 days compared with controls (adjusted OR = 2.49, 
95% CI = 1.76 to 3.53)11. 
 
The evidence base to define the safety and effectiveness of MT for selected acute 
ischaemic stroke patients has grown recently, with THERAPY12, THRACE13 and 
PISTE14 RCTs all reporting in 2016. An updated evidence synthesis is therefore 
warranted to understand the impact of these new trials on our understanding of the 
clinical effectiveness and safety of MT; in particular with stent retrievers and modern 
aspiration devices.  
 
Meta-analyses of RCTs increase the power and precision of the estimated intervention 
effects. However, RCTs of MT over time have evaluated a range of devices and the 
population considered eligible for treatment has changed. There is therefore a need to 
ensure that only those RCTs that reflect the current practice to be considered. Trial 
sequential analysis (TSA) corresponds to group sequential analysis of a single trial and 
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can be applied to meta-analysis to evaluate the robustness of the evidence. TSA 
necessitates the use of an information size to evaluate the strength of the evidence. 
There is a need to inform/estimate that pre-specified intervention effect, in the same 
manner as a power calculation in a clinical trial. TSA can help to quantify whether 
meta-analyses are presenting the best available and/or sufficient evidence. 
 
Therefore we conducted a systematic review with meta-analysis alongside TSA, that 
aimed to update the evidence-base for MT, and evaluate the benefits, risks and impact 
of three recent trials on the magnitude/uncertainty of the estimate for clinical 
effectiveness and safety of MT in the treatment of acute ischaemic stroke.  
 
METHODS 
The review adhered to a published protocol15 and the reporting guidelines of the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
statement16. 
 
Randomised clinical trials RCTs and non-randomised controlled studies (non-
randomised RCTs, controlled before-and-after studies and cohort studies with 
prospective assessment) that included a minimum of 10 adult patients (aged ≥ 18) 
presenting with acute ischaemic stroke receiving MT (stent retrievers and modern 
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aspiration devices) with or without adjuvant IVT or standard medical care were eligible 
for inclusion in the review. Where applicable, data on comparator interventions (IVT 
and other forms of best medical or supportive care) of studies evaluating MT were 
extracted. Single center studies, case control studies, cross-sectional studies and case 
series were excluded. 
 
Eligible studies had to include at least one of the following outcomes assessed at ≥ 90 
days follow-up: modified Rankin Scale (mRS)17, Oxford Handicap Scale (OHS)18, 
National Institute of Health Stroke Scale (NIHSS)19 or Barthel ADL Index20. Data on 
secondary outcomes were extracted from eligible studies: length of stay/time in acute 
care; recanalisation (Treatment in Cerebral Infarction [TICI] score21 as a reference 
measure that can be mapped onto analogous measures such as the Thrombolysis in 
Myocardial Ischemia [TIMI] score22) and EQ-5D23 (or analogous measures of health-
related quality of life). Safety of MT was summarised as a function of 90-day mortality, 
and SICH within 7-days (as per the SITS-MOST definition ‘NIHSS scores worsening ≥ 
4 within 24 hours and an intracerebral haemorrhage type PH2’24). 
 
Search strategy 
A search strategy was designed with assistance from an experienced information 
scientist (SR) using a combination of MeSH/thesaurus terms and keywords. The 
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following bibliographic databases were searched up to mid-February 2015: MEDLINE, 
EMBASE, Cochrane Central Register of Controlled Trials, SCOPUS, and Web of 
Science. Additionally several trials registries were searched: ClinicalTrials.gov, 
International Standard Randomised Controlled Trial Number Register and the Chinese 
Clinical Trial Registry. Where published protocols for ongoing randomised trials were 
identified by the search strategy (to mid-Feb 2015), these were included if published by 
end of 2016 to ensure that the evidence presented in the review is complete and up-to-
date. 
 
An example search strategy for MEDLINE can be found in Appendix 1. As our focus 
was on MT with stent retriever devices and modern current generation aspirational 
devices, studies published prior to January 2009 were excluded. No restrictions were 
placed on country of origin. Included studies had to involve humans, and had to have a 
title and abstract in English. Where available, a search filter for controlled trials25 was 
used or adapted as appropriate. Hand searching of reference lists and citation searching 
of studies that fulfilled the eligibility criteria were undertaken. References lists of 
directly relevant reviews identified by the search strategy were also hand-searched.  
 
Study selection 
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In stage 1, two reviewers (RF and EGA) independently assessed the titles and abstracts 
retrieved via the search strategy for eligibility. In stage 2, studies retained at stage 1 
were independently assessed for eligibility by PW, RF and AC using a study selection 
form (Appendix 2). Disagreements were resolved via discussion or via a third reviewer 
(PW or AC) adjudicating on inclusion of a study. 
 
Data extraction and risk of bias assessment  
A structured data extraction form, with selected items from the template for intervention 
description and replication [TIDIER] checklist26 was used to capture information on the 
study population, intervention(s), comparator(s) and outcomes (Appendix 3). Data 
extraction was undertaken by one reviewer (PW) with fidelity of data extraction 
checked by a second reviewer (RF and KH) with disagreements resolved via discussion. 
The methodological quality assessment framework for RCTs developed by the 
Cochrane Collaboration27 was used independently by two reviewers (RF and DF) to 
assess the risk of bias within studies (low, medium and high). Where applicable, 
corresponding study authors were contacted to request missing data. 
 
Data Synthesis 
Data on clinical outcomes were synthesised using meta-analytic techniques where 
sufficient data for calculation of effect sizes existed for each outcome of interest 
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(unadjusted odds ratios and corresponding 95% confidence intervals). To allow for 
differences between/within studies, random effects models were utilised. Risk of small 
study bias across studies was established with funnel plots. The later three trials were all 
stopped early (truncated) due to beneficial treatment effects. There has been some 
debate in the literature around the inclusion of truncated and non-truncated trials in a 
meta-analysis. Historically, the standard approach has been to incorporate truncated 
RCTs without any special consideration, however fears that early stopping may be an 
important source of bias has led to further investigation. A comprehensive investigation 
of the issues has concluded that early stopping of clinical trials is not a substantive 
source of bias in meta-analyses and recommend that all studies (truncated and non-
truncated) be included28.  
 
Trial Sequential Analysis 
A TSA was used to establish the optimal size within our meta-analysis (maintaining 
Type I error of 0.05 / 5%) after accounting for heterogeneity (diversity) between trials. 
The TSA was conducted using TSA software version 0.9.5.5 Beta29. An estimated 
optimal information size requirement was calculated using conventional parameters 
(power = 0.80, Type II error = 0.20; Type I error = 0.05). Based on a previous TSA of 
thrombectomy trials30 the following assumptions were made in the current TSA: a 
threshold of 30% relative risk increase for functional independence (mRS 0 to 2); 30% 
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relative risk reduction for both all-cause mortality and SICH; and control event rates of 
pooled control arm rates from the eight trials (30.4%, 17.5% and 4.7%) for functional 
independence (mRS 0 to 2), mortality and SICH respectively. Trial data were entered 
into the TSA in order of publication date.  
 
TSA enables the estimation of information size with adjusted threshold for statistical 
significance – sequential monitoring boundaries30. If the cumulative z-statistical curve 
crosses the sequential monitoring boundaries, then it can be inferred that future trials 
would not alter the conclusions about the outcome, and a sufficient level of evidence 
has been accumulated30.  When the z-curve crosses over into the futility area, it can be 
inferred that any differences between the comparators would be unlikely to change in 
future trials of MT30. 
 
FINDINGS  
Out of 4,993 records identified by the search strategy, eight randomised clinical trials 
were assessed to be eligible for inclusion in the meta-analyses (Figure 1). The eight 
trials had a combined sample size of 1,841 (916 patients treated with MT and 925 
treated without MT). However, the N in the treatment group across the trials for the 
different outcomes was variable. We also identified discrepancies in numbers of cases 
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reported in individual published trials compared with the numbers of cases reported in 
previous meta-analyses (Appendix 4). 
 
The countries of origin of the eight trials were: Australia and New Zealand (EXTEND-
IA31); Canada, Ireland, South Korea, UK and USA (ESCAPE32); Spain 
(REVASCAT33); Austria, Denmark, France, Germany, Spain, Switzerland, USA 
(SWIFT PRIME34); The Netherlands (MR CLEAN8); Germany and USA 
(THERAPY12); France (THRACE13); and UK (PISTE14). 
 
The device types, imaging modalities and recanalisation rates for patients treated with 
MT in the eight trials are shown in Table 1. All eight trials were assessed to have a low 
risk of bias (Table 2).   
 
Synthesis of results 
Functional independence  
Patients treated with MT compared with those receiving IVT and other forms of best 
medical or supportive care were more significantly more likely to be functional 
independent (mRS 0 to 2) at 90-days follow-up (OR = 2.39, 95% CI= 1.88 to 3.04) 
based on data from five trials (Figure 2). The additional impact of the three recent trials 
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was a slightly decreased pooled effect size, but with increased certainty of the mid-point 
estimate (OR = 2.07, 95% CI = 1.70 to 2.51). 
 
Mortality 
Patients treated with MT compared with those receiving IVT and other forms of best 
medical or supportive care did not show any effect on mortality at 90-days follow-up 
(Figure 3). The addition of the three most recent trials did not impact on mortality, but 
there was increased certainty of the mid-point estimate with a continuing trend towards 
reduced mortality. 
 
SICH 
Patients treated with MT compared with those receiving IVT and other forms of best 
medical or supportive care (Figure 4) did not show any statistically significant increased 
likelihood of SICH within 7 days based on data from 5 trials. Data from the PISTE trial 
were not estimable in this meta-analysis, as there were no events recorded of SICH 
within 7 days for either the treatment or the control group. Inclusion of the remaining 
two recent trials did not impact on probability of SICH. 
 
Findings of the Trial Sequential Analysis (TSA) 
A series of TSA were undertaken using data from eight randomised clinical trials. 
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Functional independence TSA 
The adjusted 95% CI for the TSA was 1.55 to 2.76 (heterogeneity = 0%). The adjusted 
information size estimate was N = 724. Figure S1 (Appendix 5) shows that the 
cumulative z-statistic curve crossed the sequential monitoring boundary for benefit of 
MT. The TSA demonstrates robust evidence for a 30% relative benefit for MT 
compared with IVT for mRS 0 to 2.  
 
Mortality TSA 
The TSA analysis (Figure S2, Appendix 5) shows that the cumulative z-statistic curve 
failed to cross the traditional boundaries for statistical significance; despite surpassing 
the diversity adjusted information size requirement (N=1,803), suggesting a lack of 
robust evidence to demonstrate a 30% relative risk reduction for MT over IVT. The 
TSA results suggest that future trials of MT are unlikely to demonstrate a significant 
effect on mortality as the adjusted 95% CI was 0.57 to 1.13. 
 
SICH TSA 
The TSA-adjusted 95% CI was 0.53 to 2.78 (diversity = 0). The diversity adjusted 
information size was estimated to be N = 6,057; this number was not reached, 
suggesting that the meta-analysis is underpowered for the SICH outcome. Figure S3 
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(Appendix 5) shows that the cumulative z-statistic curve failed to cross the convention 
statistical significance boundary, nor does it cross the boundary for futility, which 
indicates that future trials may show differences for SICH between MT and IVT.  
 
DISCUSSION  
Data from the five MT randomised clinical trials reporting in 2015 yielded significantly 
increased likelihood of functional independence (mRS 0 to 2) at 90-days follow-up (OR 
= 2.39, 95% CI= 1.88 to 3.04). The impact of the increased evidence base for MT 
(THERAPY12, THRACE13, PISTE14) was a marginally decreased effect size, but with 
increased certainty as shown by CIs with a narrower range (mRS 0 to 2; OR = 2.07, 
95% CI = 1.70 to 2.51). These findings further confirm the effectiveness of MT, in 
particular with stent retrievers and modern aspiration devices.  Compared with other 
meta-analyses of MT in the treatment of acute ischaemic stroke, including the recent 
Hermes meta-analysis9-11, our effect size for functional independence is smaller in 
magnitude.   
 
Our pooled effect size for functional independence derived from the 5 RCTs published 
in 2015 differed to previous meta-analyses, including meta-analysis conducted by the 
Hermes collaboration11. This can be explained by discrepancies in primary dichotomous 
study data (Appendix 4) and calculating unadjusted (as opposed to adjusted) odds ratios. 
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RCTs often adjust their analyses for prognostic factors which are thought to influence 
outcomes (e.g age, severity). Trials published in 2015 used both unadjusted and 
adjusted pooled effect sizes, and it is worth noting that the latter are unlikely to have 
been adjusted using the same variables. There is no consensus about whether, or how to 
pool adjusted and unadjusted findings, although it is regarded best practice to avoid this 
approach. The simplest option to avoid heterogeneity due to the differences in 
adjustment with each RCT is to report unadjusted pooled effects, as we have done here. 
 
Consistent with previous meta-analyses of MT in the treatment of stroke11, we identified 
no impact on previous estimates of safety (i.e. no increased risk of mortality and SICH 
at 90 days and 7-days respectively). Although our meta-analyses showed a trend that 
MT may lead to a decreased risk of mortality this effect was not statistically significant. 
In the case of SICH, the divergent definitions and low event rates across the eight trials 
may have confounded the overall effect for this outcome. A trial sequential analysis 
confirmed that the meta-analyses fulfilled the information size requirement to satisfy the 
criterion for ‘sufficient evidence’ on the effectiveness, but not all safety outcomes for 
MT. The information requirement was met for mortality at 90 days; however 
uncertainty remains as to whether MT is associated with increased risk of SICH. The 
robustness of efficacy data for MT would likely prohibit further randomised clinical 
trials of MT versus no MT. Further data on mortality and SICH could reliably be 
17 
 
obtained from on-going or planned trials of MT versus MT plus intravenous 
thrombolysis. 
 
Questions remain around how best to image/triage emergent LAO stroke and optimal 
MT device types, including technical questions such as use of stentrievers or aspiration, 
including issues around use of different modes of anaesthesia35 which are currently 
being addressed in on-going trials36,37. Efficacy of either MT or IVT for Wake up Stroke 
(wUS) / stoke of unknown time onset (SUTO) is also unclear. 
 
Our findings make a strong case that no further trials to evaluate the effectiveness of 
MT versus IVT aloneno MT are warranted. Our meta-analyses included patients from 
different healthcare systems, patient characteristics and a range of devices which shows 
the generalisability of effectiveness and safety of MT (with uncertainty around SICH). 
This assertion is strengthened by our use of full systematic review methodology 
(including considerations of non-English language literature) and a supplementary trial 
sequential analysis to establish the robustness of the effect sizes with reference to a 
specified information size. We also included substantially more patient numbers treated 
with modern MT compared with previous meta-analyses. 
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There is uncertainty regarding generalisability of published trials to  populations of non-
European ancestry (and countries where there may be marked differences in concomitant 
healthcare systems); however, given the compelling evidence for the efficacy of MT, it is 
unlikely that further randomised clinical trials of MT versus no MT will be undertaken. 
Therefore, registry data in other populations will be important to confirm that outcomes and 
safety in different populations and healthcare systems are consistent with existing trial data.  
 
Subgroups in many categories are still small especially if the query is broken down by 
any categorisation of trials e.g. advanced imaging selection/all IVT control or timing of 
MT since onset from symptoms. Furthermore, we did not have access to individual 
patient data (IPD). However, the IPD meta-analysis undertaken by the Hermes 
collaboration11 has already reported on patient-level evidence favouring treatment with 
MT (patients aged ≥ 80 years, patients randomised > 300 min after symptom onset, and 
patients not eligible for IVT). An updated meta-analysis of individual patient is 
planned38, and this will add further evidence in terms of sub-groups with differential 
effectiveness and safety of MT.  
 
Given the robustness and generalisability of the evidence base for MT, there is a 
pressing need to invest in acute stroke care services to support delivery of this complex 
high technology service to all eligible patients. In the UK, few centres provide 24/7 MT 
and there is large variability between services in MT pathways and delivery39. A recent 
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study has also shown that 10% of all stroke admissions in the UK could benefit from 
MT40. However, there are limitedEconomic analyses of MT indicate substantial gains in 
quality adjusted life years and cost-savings41,42, with one analysis reporting larger gains 
for younger patients42 data on costs . Costs or cost effectiveness of MT to inform 
service re-design currently. This  is currently the subject of much research in the UK 
and elsewhere43. 
 
CONCLUSIONS 
The expanded evidence base for MT yielded a more accurate precise assessment of 
effectiveness in terms of functional independence (mRS 0 to 2), with no increased risk 
of mortality or SICH. Uncertainty remains as to whether MT reduces mortality or is 
associated with increased risk of SICH.  
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Table 1. Summary of device type, imaging modality and recanalisation in the eight trials 
 
 
Primary 
author; Study 
Name 
Device Type Advanced 
Imaging* 
Recanalisation % 
Berkhemer  
2015; MR 
CLEAN8 
Trevo retrievable stents and others No MT treatment group = 115/196 
(59) 
Campbell 
2015; 
EXTEND:IA31 
Solitaire FR retrievable stent CT 
perfusion 
imaging 
IV rt-PA plus MT = 25/35 (86) 
Goyal 2015; 
ESCAPE32 
Retrievable stents or aspiration  Yes IV rt-PA plus MT =113/156 
(72) 
Jovin  2015; 
REVASCAT33 
Solitaire FR Y (in 
defined 
subgroups) 
IV rt-PA within 4.5h plus MT = 
67/103 (65) 
Saver 2015; 
SWIFT 
PRIME34 
Solitaire FR or Solitaire 2  Y (in a 
majority) 
IV-tPA plus MT = 73/83 (88) 
Mocco 2016; 
THERAPY12 
Penumbra, Solitaire or Trevo No IV rt-PA plus MT = 30/43 (70) 
Bracard 2016; 
THRACE13 
Merci, Penumbra, Catch, Solitaire Y (MRI in a 
majority) 
IV rt-PA plus MT = 95/138 (69) 
Muir 2016; 
PISTE14 
Any CE-marked device approved 
for MT (stentrievers or aspiration) 
No IV rt-PA plus MT = 26/30 (87) 
 
*Advanced imaging is taken as use of MRI techniques, Perfusion CT or a systematic 
combination of CTA collateral scoring and ASPECTS on CT brain (ESCAPE trial) 
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Table 2. Methodological Quality and Risk of Bias Assessment 
 
Primary Author; 
Study Name 
Power 
calculation 
Sample size 
achieved 
(reason for 
stopping early) 
Attrition 
(n/%) 
Adequate 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants / 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data  
Selective 
outcome 
reporting 
Free of 
other 
problems 
Overall 
Risk of 
Bias 
Berkhemer  2015;  
MR CLEAN8 
Yes Yes 2/0.4% Low risk Low risk High risk** Low risk Low risk Low risk Low risk Low  
Campbell 2015; 
EXTEND:IA31 
Yes No 
(Efficacy) 
N/A Low risk Low risk High risk** Low risk N/A Low risk Low risk Low  
Goyal 2015; 
ESCAPE32 
Yes No  
(Efficacy) 
N/A Low risk Low risk High risk** Low risk N/A Low risk Low risk Low  
Jovin  2015; 
REVASCAT33 
Yes No  
(Efficacy) 
N/A Low risk Low risk High risk** Low risk N/A Low risk Low risk Low  
Saver 2015;  Yes No N/A Low risk Low risk High risk** Low risk N/A Low risk Low risk Low  
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SWIFT PRIME34 (Efficacy) 
Mocco 2016; 
THERAPY12 
Yes  No 
(Loss of 
equipoise) 
N/A Low risk Low risk High risk** Low risk N/A Low risk Low risk Low 
Bracard 2016; 
THRACE13 
Yes No 
(Efficacy) 
N/A Low risk Low risk High risk** Low risk N/A Low risk Low risk Low  
Muir 2016;  
PISTE14 
Yes No 
(Loss of 
equipoise) 
N/A Low risk Low risk High risk** Low risk N/A Low risk Low risk Low  
 
** Not feasible to blind interventionists and was unlikely to have biased outcome in these trials 
 
 
